Importantly, elevated GATAD2B expression correlated with poor patient survival specifically in KRAS-driven lung cancer as determined by Rousseaux et al., further suggesting that GATAD2B may enhance KRAS-driven tumor growth in lung adenocarcinoma patients (HR = 1.83, P = 0.035, log rank test; Fig. 2f)33,34. This evidence concerns the gene GATAD2B and lung adenocarcinoma.